ММВБ 2 943 0,2%  Nasdaq 8 527 -0,5%  Биткойн 7 926 -2,1%  USD/RUB 63,7145 -0,2% 
РТС 1 455 0,5%  S&P500 3 108 -0,4%  Нефть 62,3 -0,3%  EUR/RUB 70,6345 -0,1% 
Dow 27 821 -0,4%  FTSE100 7 241 -0,3%  Золото 1 469 -0,2%  EUR/USD 1,1086 0,1% 

Курс акций Novartis [ISIN: CH0012005267]

купить
продать

Novartis AG - Профиль

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Акционеры

Название Доля (%)
Freefloat0,84
Novartis AG0,09
Sandoz Family Foundation0,03
Novartis Foundation For Employee Participation0,03
Government Pension Fund - Global (the)0,02
Vanguard Health Care Fund0,01
Vanguard Total International Stock Index Fund0,01
Vanguard Developed Markets Index Fund0,01
American Funds Europacific Growth Fund0,01
American Funds Capital World Growth & Income Fund0,01
Capital Income Builder0,01
Robeco Capital Gr. Fds. - Bp European Premium Equities0,00
Kempen European High Dividend Fund0,00
Nn (l) - Global High Dividend0,00
Privatdepot 40,00

Адрес

Lichtstrasse 35, 4056 Basel
а/я:
Телефон: 41.61.324.11.11
Факс: 41.61.324.80.01
Вэб: http://www.novartis.com

Менеджмент

Bertrand Bodson
Chief Digital Officer
Klaus Moosmayer
Chief Ethics Risk & Compliance Officer
Vasant Narasimhan
Chief Executive Officer
Harry Werner Kirsch
Chief Financial Officer
John Tsai
Chief Medical Officer
Elizabeth Theophille
Chief Technology & Digital Officer
Patrice Bula
Director
Mark Levick
Global Head
Lilli Petruzzelli
Global Head-Immuno-Oncology
Samir Shah
Global Head-Investor Relations
Dan Bar-Zohar
Global Head-Neuroscience Development
Stephen Moran
Global Head-Strategy
Steffen Lang
Global Head-Technical Operations
Shannon Thyme Klinger
Group General Counsel
Samit Hirawat
Head- Global Oncology Development
Mark Never
Head-Cluster Western Europe
Ameet Mallik
Head-Global Marketing, Value & Access
Steven Baert
Head-Human Resources
Natacha Theytaz
Head-Internal Audit
Hans Jörg Reinhardt
Independent Non-Executive Chairman
William Thomas Winters
Independent Non-Executive Director
Nancy C. Andrews
Independent Non-Executive Director
Mary Elizabeth Doherty
Independent Non-Executive Director
Andreas von Planta
Independent Non-Executive Director
Ann Marie Fudge
Independent Non-Executive Director
Ton Büchner
Independent Non-Executive Director
Frans van Houten
Independent Non-Executive Director
Srikant T. Madhav Datar
Independent Non-Executive Director
Charles L. Sawyers
Independent Non-Executive Director
Janneke van der Kamp
Member Executive Committee
James E. Bradner
Member-Executive Committee
David Lebwohl
SVP & Franchise Global Program Head
Charlotte Pamer-Wieser
Secretary
Charlie Hough
VP & Global Head-Strategy
Mimi Huizinga
VP & Head-Strategic Data
Enrico Cipro Vanni
Vice Chairman
Jeffrey Engelman
Vice President & Global Head-Oncology NIBR

Добавить или редактировать инструмент